Brooke Harmon, a virologist at Sandia National Laboratories, led research that found a cellular pathway for Rift Valley fever virus infection, the first step in developing treatment for the highly infectious deadly disease. (Image courtesy of the Sandia National Laboratories/Randy Wong)
Viruses can’t live without us — literally. As obligate parasites, viruses need a host cell to survive and grow. Scientists are exploiting this characteristic by developing therapeutics that close off pathways necessary for viral infection, essentially stopping pathogens in their tracks.
Rift Valley fever virus (RVFV) and other members of the bunyavirus family may soon be added to the list of viruses denied access to a human host. Sandia National Laboratories researchers have discovered a mechanism by which RVFV hijacks the host machinery to cause infection. This mechanism offers a new approach toward developing countermeasures against this deadly virus, which in severe human infections causes fatal hepatitis with hemorrhagic fever, encephalitis and retinal vasculitis.
The results are reported in a paper, “A Genome-Wide RNAi Screen Identifies a Role for Wnt/Beta-Catenin Signaling During Rift Valley Fever Virus Infection,” recently published in the Journal of Virology. The work was funded by Sandia’s Laboratory Directed Research and Development program.
RVFV uses a Cancer Pathway
Little is known about the fundamental infection mechanisms and interactions between bunyaviruses and their host cells. Led by Sandia virologist Brooke Harmon, the researchers discovered that Wnt signaling is essential for bunyavirus infection.
The Wnt signaling pathway, which regulates critical cell processes, such as proliferation and differentiation, is already under heavy investigation by medical researchers because of its association with breast, melanoma, prostrate, lung, ovarian and other cancers and with Type II diabetes. Clinical trials are underway for cancer treatments targeting the Wnt pathway.
“We can take advantage of the work on cancer therapeutics. Inhibitors of this pathway are already being developed for several cancers. As those therapies move through clinical trials, we can apply them to infectious diseases,” said Harmon.
Rift Valley a Priority Pathogen
You may not have heard of RVFV, but it’s a familiar threat to anyone working in infectious diseases. The National Institute of Allergy and Infectious Diseases lists RVFV as a category A priority pathogen, meaning it poses the highest risk to national security and public health.
“Rift Valley combines some of the most sinister aspects of both Ebola and Zika into one virus,” explained Harmon. “Like Ebola, it can cause hemorrhagic fever and be lethal within days of infection. Like Zika, it’s transmitted by mosquitoes, can cause neurological disease in humans, and results in frequent miscarriages and fetal deformities in livestock.”
Today RVFV predominantly affects animals, livestock in particular. Like most viruses transmitted by mosquitos, RVFV circulates predominantly in wild animals but has the potential to spill over into human populations, similar to avian influenza and West Nile virus.
While endemic to Africa, RVFV has spread to the Arabian Peninsula and has the capacity to emerge into further territories. Since the late 1990s, large-scale RVFV outbreaks in eastern and southern Africa, Mauritania, Saudi Arabia and Yemen have severely affected the health and economy of tens of thousands of humans and infected hundreds of thousands of livestock.
Bunyavirus Family uses Wnt
Harmon and Sandia researcher Oscar Negrete began the project about five years ago by using high-throughput RNA interference to screen the entire human genome against RVFV. The researchers looked for genes that were required for virus infection, meaning that the virus cannot infect cells missing that gene.
From that initial screen, conducted at the University of California, Berkeley, and further screening at Sandia, they narrowed the field down to 381 genes of interest. “When we functionally clustered those genes, we found that the Wnt pathway was the most represented,” said Negrete.
To test their hypothesis that the Wnt pathway is critical to RVFV infection, the researchers tested a vaccine strain of the virus. When those results supported their theory, they conducted the same experiments on wild type virus in a Biosafety Level-3 laboratory at Lawrence Livermore National Laboratory.
They expanded the testing to other members of the bunyavirus family like La Crosse virus and California encephalitis virus and found the same results. “This was somewhat unexpected because divergent bunyaviruses typically have their own unique features of infection. The fact that they shared this same pathway is exciting because it indicates Wnt signaling may be necessary to the virus family as a whole,” said Negrete.
Getting Ahead of the Next Big Outbreak
The next step, said Negrete, is to further investigate the mechanisms of infection. The researchers also plan to look for other mechanisms of RVFV infection using CRISPR, or clustered regularly interspaced short palindromic repeats, which is complementary to RNA interference. This understanding can aid in the design of effective host-directed anti-viral therapeutics.
“We keep chasing these viruses. An outbreak like Zika happens and that’s when the push begins for a therapeutic. We need to get out in front of the next big one because recent history has taught us that deadly diseases can rapidly spread from animals to humans and beyond endemic zones,” said Harmon. “If there is an outbreak of RVFV or another bunyavirus, we hope to already have something in the arsenal.”
Sandia National Laboratories is a multi-program laboratory operated by Sandia Corporation, a wholly owned subsidiary of Lockheed Martin Corp., for the U.S. Department of Energy’s National Nuclear Security Administration. With main facilities in Albuquerque, N.M., and Livermore, Calif., Sandia has major R&D responsibilities in national security, energy and environmental technologies and economic competitiveness.
Sandia News Media Contact:
Patti Koning, (925) 294-4911
About this Publication:
The appearance of external hyperlinks in this publication does not constitute endorsement by the HDIAC or the United States Department of Defense (DoD) of the linked sites, nor the information, products, or services contained therein. The HDIAC is a DOD sponsored Information Analysis Center (IAC), with policy oversight provided by the Assistant Secretary of Defense for Research and Engineering (ASD(R&E)), and administratively managed by the Defense Technical Information Center (DTIC). Reference herein to any specific commercial products, process, or services by trade name, trademark, manufacturer, or otherwise, does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States Government or the HDIAC. For permission and restrictions on reprinting, please contact firstname.lastname@example.org.